IZOTROPIC
CORPORATION
CSE: IZO | OTC: IZOZF | FSE: 1R3

Suite 424, 800-15355 24th Avenue,
Surrey BC V4A 2H9
1-833-IZOCORP | www.izocorp.com

- **USD $3M Clinical Trial Underway**
- **31% Ownership by Insiders & Management**

Fact Sheet - September 2020

Izotropic Corporation is a publicly listed company, established to commercialize a new breast imaging technology called "breast computed tomography" (BCT) for early stage detection and diagnosis of breast cancers.

Unlike the current best of care breast imaging devices in use, the company's true 3D imaging system provides very high resolution imaging with 360° view acquisition. Imaging time is fast taking only 10 seconds per breast with no discomfort, as breast compression is not required.

Clinical trials underway have demonstrated that BCT can identify early stage indicators in breast tissue and more accurately determine tumor size, shape, and location. Trials have also demonstrated fast and efficient detection and diagnosis of both benign and cancer-causing lesions in the 3-5mm range, which is less than half the current average size imaged using mammography, with a comparable radiation dose.

Izotropic Breast CT Imaging System



True 3-D Images
All images are viewable from any angle

High Resolution
Images that are high-quality and are crystal-clear

Fast Imaging
500 uncompressed images in 10 seconds

No Discomfort
No Painful Breast Compression

Radiation Dose
Comparable to Standard of Care Mammography

Comparable to Breast MRI
The 3D standard for imaging high-risk women

These trials have included thousands of images to date, taken on hundreds of patients, using fully functioning BCT prototype models. BCT performance is comparable to MRI which is the current standard of care for imaging high risk patients.

In addition to investor funds, approximately $20M USD in government grants has been invested to develop this ground-breaking technology at UC Davis Medical Center in Sacramento, CA. Recently granted US patents for the use of BCT to measuring breast density and to perform robotic guided biopsy are expected to add to the value proposition.

The company believes BCT will pave the way to earlier detection and become a welcome addition to radiology departments in future because of its ability to provide very high-resolution images from multiple angles. The company also believes that the use of BCT will help to lower false negative and false positive diagnosis. After many years in development and testing stages, the first commercial BCT imaging device is scheduled for completion before the end of 2020. After FDA approval is obtained, marketing will be initially focused in the US.

Shares Outstanding
30,155,499

Warrants Issued
6,509,000

52 Week Range
$0.1150 - 0.8400 CDN
$0.0814 - 0.6500 US

Corporate Information

Transfer Agent:
Odyssey Trust Company
Law Firm: Clark Wilson LLP
Auditor: DMCL
US Patent Attorney:
Venable LLP